Physician profile
Todd D Miller
NPI 1245342112
$9,209.10
in general payments reported to CMS, 2019-2025
54 companies · $845 in 2025
The $845 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $1,170 · 2021: $1,489 · 2022: $1,504 · 2023: $1,842 · 2024: $1,540 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,233.75 | 2019-2025 | |
| Novo Nordisk INC | $1,273.86 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $691.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $448.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $395.22 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Allergan, INC. | $368.66 | 2019-2020 | |
| Lilly USA, LLC | $314.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $279.26 | 2020-2023 | |
| Kowa Pharmaceuticals America, INC. | $226.35 | 2019-2024 | Livalo, Seglentis |
| Astellas Pharma US INC | $220.80 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $173.86 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Axsome Therapeutics, INC. | $170.50 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $163.35 | 2019-2025 | Breztri, Farxiga |
| Abbott Laboratories | $152.88 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $134.72 | 2020-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.